TY - JOUR
T1 - Estimation of sarcopenia prevalence using various assessment tools
AU - Beaudart, C.
AU - Reginster, J. Y.
AU - Slomian, J.
AU - Buckinx, F.
AU - Dardenne, N.
AU - Quabron, A.
AU - Slangen, C.
AU - Gillain, S.
AU - Petermans, J.
AU - Bruyère, O.
N1 - Funding Information:
Charlotte Beaudart is supported by a Fellowship from the FNRS (Fonds National de la Recherche Scientifique de Belgique — FRS-FNRS — www.frs-fnrs.be ).
Publisher Copyright:
© 2014 Elsevier Inc.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Background: Sarcopenia is defined as a progressive and generalized loss of muscle mass with either a loss of muscle strength or a loss of physical performance but there is no recommendation regarding the diagnostic tools that have to be used. In this study, we compared the prevalence of sarcopenia assessed using different diagnostic tools. Methods: To measure muscle mass, muscle strength and physical performance, we used for each outcome two different diagnostic tools. For muscle mass, we used Dual Energy X-Ray Absorptiometry (DXA) and bio-electrical impedance analysis (BIA); for muscle strength, we used a hydraulic dynamometer and a pneumatic dynamometer; for physical performance we used the Short Physical Performance Battery test (SPPB test) and the walk speed. Eight diagnostic groups were hereby established. Results: A total of 250 consecutive subjects were recruited in an outpatient clinic in Liège, Belgium. Estimated prevalence of sarcopenia varied from 8.4% to 27.6% depending on the method of diagnosis used. Regarding muscle mass, BIA systematically overestimated muscle mass compared to DXA (mean estimated prevalence with BIA. = 12.8%; mean prevalence with DXA. = 21%). For muscle strength, the pneumatic dynamometer diagnosed twice more sarcopenic subjects than the hydraulic dynamometer (mean estimated prevalence with PD. = 22.4%; mean estimated prevalence with HD. = 11.4%). Finally, no difference in prevalence was observed when the walking speed or the SPPB test was used. A weak overall kappa coefficient was observed (0.53), suggesting that the 8 methods of diagnosis are moderately concordant. Conclusion: Within the same definition of sarcopenia, prevalence of sarcopenia is highly dependent on the diagnostic tools used.
AB - Background: Sarcopenia is defined as a progressive and generalized loss of muscle mass with either a loss of muscle strength or a loss of physical performance but there is no recommendation regarding the diagnostic tools that have to be used. In this study, we compared the prevalence of sarcopenia assessed using different diagnostic tools. Methods: To measure muscle mass, muscle strength and physical performance, we used for each outcome two different diagnostic tools. For muscle mass, we used Dual Energy X-Ray Absorptiometry (DXA) and bio-electrical impedance analysis (BIA); for muscle strength, we used a hydraulic dynamometer and a pneumatic dynamometer; for physical performance we used the Short Physical Performance Battery test (SPPB test) and the walk speed. Eight diagnostic groups were hereby established. Results: A total of 250 consecutive subjects were recruited in an outpatient clinic in Liège, Belgium. Estimated prevalence of sarcopenia varied from 8.4% to 27.6% depending on the method of diagnosis used. Regarding muscle mass, BIA systematically overestimated muscle mass compared to DXA (mean estimated prevalence with BIA. = 12.8%; mean prevalence with DXA. = 21%). For muscle strength, the pneumatic dynamometer diagnosed twice more sarcopenic subjects than the hydraulic dynamometer (mean estimated prevalence with PD. = 22.4%; mean estimated prevalence with HD. = 11.4%). Finally, no difference in prevalence was observed when the walking speed or the SPPB test was used. A weak overall kappa coefficient was observed (0.53), suggesting that the 8 methods of diagnosis are moderately concordant. Conclusion: Within the same definition of sarcopenia, prevalence of sarcopenia is highly dependent on the diagnostic tools used.
KW - Diagnostic
KW - Muscle mass
KW - Prevalence
KW - Sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=84911947856&partnerID=8YFLogxK
U2 - 10.1016/j.exger.2014.11.014
DO - 10.1016/j.exger.2014.11.014
M3 - Article
C2 - 25449859
AN - SCOPUS:84911947856
SN - 0531-5565
VL - 61
SP - 31
EP - 37
JO - Experimental Gerontology
JF - Experimental Gerontology
ER -